Article Information
History
- March 30, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maria Vlastara1,
- Raffaella Rossin1,
- Freek J.M. Hoeben2,
- Kim E. de Roode1,
- Milou Boswinkel3,
- Laurens H.J. Kleijn1,
- James Nagarajah3,
- Mark Rijpkema3 and
- Marc S. Robillard1,*
- 1Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands
- 2SyMO-Chem, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands
- 3Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands
- ↵*Correspondence and request for materials should be addressed to M.S.R. (email: marc.robillard{at}tagworkspharma.com)
Posted March 30, 2023.
Click-to-Release: Cleavable Radioimmunoimaging with 89Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
